The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in the brain.
Meanwhile, AstraZeneca’s Enhertu partner Daiichi arrived at ESMO armed with its own ADC data for the cadherin-6-targeting ...
The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...
Roche believes it has exited phase 3 with data to support talks with regulatory agencies, but the mixed results raise ...
Last week, readers were most interested in a story about alternatives to blood as sample types for diagnostic testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback